123.47

2.17% 2.62

After Hours: 123.00 -0.47 -0.38%

Celcuity Inc (CELC)

Overview News Price History Option Chain Financials Discussions Forecast

Celcuity Inc stock is traded at $123.47, with a volume of 701.49K. It is up +2.17% in the last 24 hours and up +8.10% over the past month. Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Previous Close:

$120.85

Open:

$120.41

24h Volume:

701.49K

Relative Volume:

0.98

Market Cap:

$5.97B

Revenue:

Net Income/Loss:

$-177.04M

P/E Ratio:

-32.61

EPS:

-3.7867

Net Cash Flow:

$-153.53M

1W Performance:

+5.58%

1M Performance:

+8.10%

6M Performance:

+146.79%

1Y Performance:

+1,121%

1-Day Range:

$118.28

$124.66

1-Week Range:

$115.50

$125.00

52-Week Range:

$9.50

$125.00

Celcuity Inc Stock (CELC) Company Profile

Name

Celcuity Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

763-392-0767

Address

16305 36TH AVENUE N, MINNEAPOLIS, MN

Employee

155

Twitter

Next Earnings Date

2026-03-25

Latest SEC Filings

CELC's Discussions on Twitter

Compare CELC vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CELC Celcuity Inc	123.47	5.84B	0	-177.04M	-153.53M	-3.7867
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Celcuity Inc Stock (CELC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-25	Initiated	Wells Fargo	Overweight
Nov-18-25	Initiated	Wolfe Research	Outperform
Nov-17-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-22-25	Initiated	Guggenheim	Buy
Jul-01-25	Resumed	Stifel	Buy
Jul-22-24	Initiated	Leerink Partners	Outperform
Feb-22-24	Initiated	Stifel	Buy
Dec-08-23	Initiated	H.C. Wainwright	Buy
Oct-08-21	Initiated	Canaccord Genuity	Buy
Sep-07-21	Initiated	Jefferies	Buy
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy
Jan-28-21	Reiterated	H.C. Wainwright	Buy
Dec-24-20	Reiterated	H.C. Wainwright	Buy
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy

View All

Celcuity Inc Stock (CELC) Latest News

Apr 13, 2026

Aug Setups: Is Celcuity Inc stock a smart retirement pick2026 Trading Recap & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

Celcuity stock hits all-time high at $120.4 USD By Investing.com - Investing.com India

Apr 09, 2026

Pullback Watch: Whats the beta of Celcuity Inc stock2026 Short Interest & Smart Allocation Stock Reports - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

(CELC) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Apr 08, 2026

Aug Big Picture: Is Celcuity Inc stock a falling knife or bargain buy2026 Trading Volume Trends & Intraday High Probability Setup Alerts - baoquankhu1.vn

Apr 08, 2026

Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending - Sahm

Apr 08, 2026

Apr 07, 2026